These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 35024413)

  • 1. Assessment and management of the heightened risk for atherosclerotic cardiovascular events in patients with lupus erythematosus or dermatomyositis.
    Keyes E; Grinnell M; Jacoby D; Vazquez T; Diaz D; Werth VP; Williams KJ
    Int J Womens Dermatol; 2021 Dec; 7(5Part A):560-575. PubMed ID: 35024413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. State of current management of the heightened risk for atherosclerotic cardiovascular events in an established cohort of patients with lupus erythematosus.
    Zhao M; Feng R; Werth VP; Williams KJ
    Lupus Sci Med; 2023 Aug; 10(2):. PubMed ID: 37604650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment patterns of lipid-lowering therapies and possible statin intolerance among statin users with clinical atherosclerotic cardiovascular disease (ASCVD) or diabetes mellitus (DM) in Taiwan.
    Chen WJ; Wen YC; Fox KM; Shen LJ; Lin LY; Qian Y; Zhao Z; Rane PP; Hsiao FY
    J Eval Clin Pract; 2020 Aug; 26(4):1171-1180. PubMed ID: 31646715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT
    Circulation; 2019 Jun; 139(25):e1144-e1161. PubMed ID: 30586775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT
    J Am Coll Cardiol; 2019 Jun; 73(24):3210-3227. PubMed ID: 30423394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atherosclerotic cardiovascular disease risk assessment: An American Society for Preventive Cardiology clinical practice statement.
    Wong ND; Budoff MJ; Ferdinand K; Graham IM; Michos ED; Reddy T; Shapiro MD; Toth PP
    Am J Prev Cardiol; 2022 Jun; 10():100335. PubMed ID: 35342890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Different Low-Density Lipoprotein-Lowering Medications on Secondary Prevention of Atherosclerotic Cardiovascular Disease in Patients With Diabetes Mellitus.
    Saag JL; Gross D; Stirt D; Espina Rey A; Gros B
    Cureus; 2023 Jun; 15(6):e40905. PubMed ID: 37492827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease.
    Chan J; Rajalingam T; Fossella J; Zhou H; Eisenberg N; Roche-Nagle G
    Ann Vasc Surg; 2020 Nov; 69():197-205. PubMed ID: 32554202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. There is urgent need to treat atherosclerotic cardiovascular disease risk earlier, more intensively, and with greater precision: A review of current practice and recommendations for improved effectiveness.
    Makover ME; Shapiro MD; Toth PP
    Am J Prev Cardiol; 2022 Dec; 12():100371. PubMed ID: 36124049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beta-blockers for Atherosclerosis Prevention: a Missed Opportunity?
    Vrablik M; Corsini A; Tůmová E
    Curr Atheroscler Rep; 2022 Mar; 24(3):161-169. PubMed ID: 35174437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aminoquinoline antimalarial therapy in dermatomyositis-are we missing opportunities with respect to comorbidities and modulation of extracutaneous disease activity?
    Sontheimer RD
    Ann Transl Med; 2018 Apr; 6(8):154. PubMed ID: 29862243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diabetes associated residual atherosclerotic cardiovascular risk in statin-treated patients with prior atherosclerotic cardiovascular disease.
    Zhao Y; Xiang P; Coll B; López JAG; Wong ND
    J Diabetes Complications; 2021 Mar; 35(3):107767. PubMed ID: 33168394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
    Ray KK; Del Prato S; Müller-Wieland D; Cariou B; Colhoun HM; Tinahones FJ; Domenger C; Letierce A; Mandel J; Samuel R; Bujas-Bobanovic M; Leiter LA
    Cardiovasc Diabetol; 2019 Nov; 18(1):149. PubMed ID: 31706300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
    Rosenblit PD
    Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing Dyslipidemia Management for the Prevention of Cardiovascular Disease: a Focus on Risk Assessment and Therapeutic Options.
    Berman AN; Blankstein R
    Curr Cardiol Rep; 2019 Aug; 21(9):110. PubMed ID: 31378838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of atherosclerotic cardiovascular disease influences the perceived need for aggressive lipid management.
    Mancini GBJ; Gupta M; Tsigoulis M; Cannon CP; Genest J; Ray KK; Santos RD; Watts GF; Raggi P
    Atherosclerosis; 2017 Aug; 263():112-118. PubMed ID: 28623740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolving Management of Low-Density Lipoprotein Cholesterol: A Personalized Approach to Preventing Atherosclerotic Cardiovascular Disease Across the Risk Continuum.
    Wilkinson MJ; Lepor NE; Michos ED
    J Am Heart Assoc; 2023 Jun; 12(11):e028892. PubMed ID: 37260036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes.
    Roe MT; Li QH; Bhatt DL; Bittner VA; Diaz R; Goodman SG; Harrington RA; Jukema JW; Lopez-Jaramillo P; Lopes RD; Louie MJ; Moriarty PM; Szarek M; Vogel R; White HD; Zeiher AM; Baccara-Dinet MT; Steg PG; Schwartz GG
    Circulation; 2019 Nov; 140(19):1578-1589. PubMed ID: 31475572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atherosclerotic Cardiovascular Disease in Diabetes Patients.
    Amelia R; Sari Wahyuni A; Yunanda Y; Wijaya H
    Curr Diabetes Rev; 2023; 19(8):e060223213457. PubMed ID: 36748224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of the 2013 Cholesterol Guideline on Patterns of Lipid-Lowering Treatment in Patients with Atherosclerotic Cardiovascular Disease or Diabetes After 1 Year.
    Tran JN; Kao TC; Caglar T; Stockl KM; Spertus JA; Lew HC; Solow BK; Chan PS
    J Manag Care Spec Pharm; 2016 Aug; 22(8):901-8. PubMed ID: 27459652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.